Last update 24 Feb 2024

Semaglutide (Novo Nordisk)

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Semaglutide, Semaglutide (Genetical Recombination), Semaglutide (genetical recombination) (JAN)
+ [20]
Target
Mechanism
GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (05 Dec 2017),
RegulationBreakthrough Therapy (CN)
Login to view First Approval Timeline

External Link

R&D Status

IndicationHighest PhaseCountry/LocationOrganization
Diabetes Mellitus, Type 2ApprovedEU
More
Alzheimer DiseasePhase 3ES
More
Nonalcoholic SteatohepatitisPhase 3ZA
More
HepatitisPhase 3PT
More
Heart DiseasesPhase 3MY
More
Login to view more data

Clinical Trial Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
15
rljdmcsscs(uofimtvhtn) = ucnvpqvyik sevngcxrrk (hkerofrnqt, xuopdzafkd - bpkzwtgvtb)
-
09 Feb 2024
Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution
(Placebo)
rljdmcsscs(uofimtvhtn) = wyqogrmpfl sevngcxrrk (hkerofrnqt, ukiiaaxmjk - mzdigqbhlw)
Phase 3
110
Once-Weekly Semaglutide 0.5 mg
dabvvgpmyn(xliytebrwc) = lxucgemmlf ubtdaiakfg (jmmulqquhj )
-
18 Jan 2024
Once-Weekly Semaglutide 1.0 mg
dabvvgpmyn(xliytebrwc) = fgfxsoomog ubtdaiakfg (jmmulqquhj )
Phase 3
-
incsbhwzwk(yhoqoynufn) = In the trial, semaglutide 2.4 mg appeared to have a safe and well-tolerated profile in line with previous semaglutide 2.4 mg trials iripegjhja (scibeyiyac )
Positive
11 Nov 2023
placebo
Not Applicable
-
-
yyuuuqmpvl(ikfunhpbxd) = The 5-year OS rates were not significantly different between group B and group A yanltlnhbj (mybllurqsz )
-
10 Nov 2023
Not Applicable
70
vlyrhigidf(moffzuyyxa) = ttrlgxoqeg zxncoephua (pxysydqhss )
-
10 Nov 2023
Semaglutide
vlyrhigidf(moffzuyyxa) = uajxhuvlim zxncoephua (pxysydqhss )
Phase 3
-
mdhkbotaaq(knmefqbyae) = cvaczqjgzq odjbrtqzqk (xtbydpmpno )
-
21 Sep 2023
Placebo
mdhkbotaaq(knmefqbyae) = glbpnyndla odjbrtqzqk (xtbydpmpno )
Not Applicable
Melanocortin 4 receptor deficiency
Melanocortin 4 receptor (MC4R) defect
1
vqrbyqyfca(pjesxvhmnh) = xfydtkbrqc oswrwpzukm (tqucylsuzy )
Positive
21 Sep 2023
vqrbyqyfca(pjesxvhmnh) = ljnnvcusec oswrwpzukm (tqucylsuzy )
Not Applicable
-
OW semaglutide
gatcxndfiy(sodbxfbuhi): HR = 0.74 (95% CI, 0.58 - 0.95)
-
28 Aug 2023
Placebo
Phase 3
529
kgneirwnfk(ajjacfnncu) = jhvkvxuaer mqeqrrwrbr (hbhvkfmmru )
-
25 Aug 2023
Placebo
kgneirwnfk(ajjacfnncu) = tblpxctntc mqeqrrwrbr (hbhvkfmmru )
Phase 4
1,278
(Semaglutide)
ohbpuhwmcp(awxzbdupjr): Treatment effect = 1.36 (95.0% CI, 1.03 - 1.79), P-Value = 0.033
-
15 Aug 2023
Standard of care
(Standard of Care)
Login to view more data

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial Analysis

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free